274 related articles for article (PubMed ID: 15561678)
1. The molecular basis of leukemia.
Gilliland DG; Jordan CT; Felix CA
Hematology Am Soc Hematol Educ Program; 2004; ():80-97. PubMed ID: 15561678
[TBL] [Abstract][Full Text] [Related]
2. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
Moore MA; Dorn DC; Schuringa JJ; Chung KY; Morrone G
Exp Hematol; 2007 Apr; 35(4 Suppl 1):105-16. PubMed ID: 17379095
[TBL] [Abstract][Full Text] [Related]
3. Childhood and adolescent lymphoid and myeloid leukemia.
Pui CH; Schrappe M; Ribeiro RC; Niemeyer CM
Hematology Am Soc Hematol Educ Program; 2004; ():118-45. PubMed ID: 15561680
[TBL] [Abstract][Full Text] [Related]
4. Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype.
Matsuno N; Osato M; Yamashita N; Yanagida M; Nanri T; Fukushima T; Motoji T; Kusumoto S; Towatari M; Suzuki R; Naoe T; Nishii K; Shigesada K; Ohno R; Mitsuya H; Ito Y; Asou N
Leukemia; 2003 Dec; 17(12):2492-9. PubMed ID: 14562119
[TBL] [Abstract][Full Text] [Related]
5. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
[TBL] [Abstract][Full Text] [Related]
6. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.
Drexler HG
Leukemia; 1996 Apr; 10(4):588-99. PubMed ID: 8618433
[TBL] [Abstract][Full Text] [Related]
7. Flt3 in acute myelogenous leukemia: biology, prognosis, and therapeutic implications.
Voutsadakis IA
Med Oncol; 2003; 20(4):311-24. PubMed ID: 14716027
[TBL] [Abstract][Full Text] [Related]
8. Genetics of myeloid leukemias.
Kelly LM; Gilliland DG
Annu Rev Genomics Hum Genet; 2002; 3():179-98. PubMed ID: 12194988
[TBL] [Abstract][Full Text] [Related]
9. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
10. FLT3-TKD mutation in childhood acute myeloid leukemia.
Liang DC; Shih LY; Hung IJ; Yang CP; Chen SH; Jaing TH; Liu HC; Wang LY; Chang WH
Leukemia; 2003 May; 17(5):883-6. PubMed ID: 12750701
[TBL] [Abstract][Full Text] [Related]
11. Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia.
Engel ME; Hiebert SW
Cancer Treat Res; 2010; 145():127-47. PubMed ID: 20306249
[TBL] [Abstract][Full Text] [Related]
12. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells.
Lin LI; Chen CY; Lin DT; Tsay W; Tang JL; Yeh YC; Shen HL; Su FH; Yao M; Huang SY; Tien HF
Clin Cancer Res; 2005 Feb; 11(4):1372-9. PubMed ID: 15746035
[TBL] [Abstract][Full Text] [Related]
13. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
Lopes de Menezes DE; Peng J; Garrett EN; Louie SG; Lee SH; Wiesmann M; Tang Y; Shephard L; Goldbeck C; Oei Y; Ye H; Aukerman SL; Heise C
Clin Cancer Res; 2005 Jul; 11(14):5281-91. PubMed ID: 16033847
[TBL] [Abstract][Full Text] [Related]
14. Molecular genetics of human leukemias: new insights into therapy.
Gilliland DG
Semin Hematol; 2002 Oct; 39(4 Suppl 3):6-11. PubMed ID: 12447846
[TBL] [Abstract][Full Text] [Related]
15. Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition.
Chen L; Chen W; Mysliwski M; Serio J; Ropa J; Abulwerdi FA; Chan RJ; Patel JP; Tallman MS; Paietta E; Melnick A; Levine RL; Abdel-Wahab O; Nikolovska-Coleska Z; Muntean AG
Leukemia; 2015 Jun; 29(6):1290-300. PubMed ID: 25650089
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.
Tse KF; Allebach J; Levis M; Smith BD; Bohmer FD; Small D
Leukemia; 2002 Oct; 16(10):2027-36. PubMed ID: 12357354
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of FLT3 mutations in pediatric non-promyelocytic acute myeloid leukemia.
Kang HJ; Hong SH; Kim IH; Park BK; Han KS; Cho HI; Shin HY; Ahn HS
Leuk Res; 2005 Jun; 29(6):617-23. PubMed ID: 15863200
[TBL] [Abstract][Full Text] [Related]
18. Leukemogenic potency of the novel FLT3-N676K mutant.
Huang K; Yang M; Pan Z; Heidel FH; Scherr M; Eder M; Fischer T; Büsche G; Welte K; von Neuhoff N; Ganser A; Li Z
Ann Hematol; 2016 Apr; 95(5):783-91. PubMed ID: 26891877
[TBL] [Abstract][Full Text] [Related]
19. Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway.
Yao Q; Nishiuchi R; Kitamura T; Kersey JH
Leukemia; 2005 Sep; 19(9):1605-12. PubMed ID: 16034464
[TBL] [Abstract][Full Text] [Related]
20. [Acute myeloid leukemia: molecular pathogenesis and new therapeutic strategies].
Goyama S
Rinsho Ketsueki; 2016 Feb; 57(2):118-28. PubMed ID: 26935629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]